News
The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...
Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...
2don MSN
CEO Lars Jørgensen is stepping down from his post after eight years in the role, during which he lead the company to an ...
However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to ...
Novo Nordisk said Wednesday that it will work with the biotech Septerna to develop oral GLP-1 obesity drugs ... royalties on global sales of approved products. The companies said they’ll ...
Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback